Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Zrt.

Gyorgyi Kovanyine Lax

Balazs Volk

Eva Sipos

Jozsef Barkoczy

Gyula Lukacs

Gyorgy Krasznai

Gyorgy Ruzsics

Balazs Havasi

Gyula Simig

Kalman Nagy

Zoltán Varga

Ferenc Lorant Bartha

Istvan Ling

Adrienn Keszthelyi

Ferenc Jurak

Andras Dancso

Maria Tothne Lauritz

Janos Imre

Eva Szabo

Éva Pécsi

Andras Boza

Imre Markovits

Krisztina Fodorné Kocsmár

Laszlo Jozsef Hegedus

Gyorgy Jeges

Maria Julia Taborine Toth

Peter Gregor

Csaba Hamori

Jeno Peter Seres

Zsolt Runge

Katalin Kataine Fadgyas

Monika Mezovari

Gyorgy Morovjan

Gabor Bagyinszki

The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula  Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.

Process for the preparation of vortioxetine salts

The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.

Process for the preparation of a rivaroxaban and intermediates formed in said process

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. 

Crystalline pharmaceutically active ingredients

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

Growing community of inventors

Budapest, Hungary

Gyorgyi Kovanyine Lax